RT Journal Article
SR Electronic
T1 Mechanical Circulatory Support for the Failing Heart: Continuous-Flow Left Ventricular Assist Devices
JF Ochsner Journal
JO Ochsner J
FD O. P. Jindal Global University
SP 263
OP 269
VO 16
IS 3
A1 Englert, Joseph A. R.
A1 Davis, Jennifer A.
A1 Krim, Selim R.
YR 2016
UL http://www.ochsnerjournal.org/content/16/3/263.abstract
AB Background: Heart transplantation remains the definitive therapy for patients with advanced heart failure; however, owing to limited donor organ availability and long wait times, continuous-flow left ventricular assist devices (LVADs) have become standard therapy.Methods: This review summarizes the history, progression, function, and basic management of LVADs. Additionally, we provide some clinical pearls and important caveats for managing this unique patient population.Results: Currently, the most common LVADs being implanted in the United States are second- and third-generation devices, the HeartMate II (Thoratec Corp., St. Jude Medical) and the HeartWare HVAD (HeartWare International, Inc.). A newer third-generation pump, the HeartMate III (Thoratec Corp., St. Jude Medical), is designed to create an artificial pulse and is currently under investigation in the United States.Conclusion: LVAD use is promising, will continue to grow, and has become standard therapy for advanced heart failure as a bridge to recovery, as destination therapy, and as a bridge to transplantation.